Thursday, June 28, 2018

U.S. oil prices rally to highest level since 2014 as crude supplies notch biggest weekly drop of the

Oil prices rallied Wednesday, with the U.S. benchmark heading toward its highest since 2014 as domestic crude supplies notched their biggest weekly drop of the year so far.

Traders also showed concerns over U.S. threats to sanction countries that don��t stop importing oil from Iran by Nov. 4.

On the New York Mercantile Exchange, August West Texas Intermediate crude CLQ8, +3.40% �tacked on $2.03, or 2.9%, to $72.56 a barrel. It��s set to top the $72.35 finish from May 21, which was the highest since November 2014. August Brent crude LCOQ8, +2.31% the global benchmark, was up $1.65, or 2.2%, to $77.96 a barrel on ICE Futures Europe, aiming for the highest finish since May.

The U.S. Energy Information Administration reported Wednesday that crude supplies declined by 9.9 million barrels for the week ended June 22��the largest weekly decline so far this year. Analysts surveyed by S&P Global Platts had forecast a fall of 2.3 million barrels, while the American Petroleum Institute on Tuesday reported a drop of 9.2 million barrels.

��Record crude exports and record refinery runs have combined to yield the biggest draw to crude stocks so far this year,�� said Matt Smith, director of commodity research at ClipperData. ��Even crude production holding at a record level has been unable to offset strong domestic and international demand.�� The EIA pegged last week��s total domestic crude output at 10.9 million barrels a day, unchanged from the previous week.

Gasoline stockpiles rose by 1.2 million barrels for the week, while distillate stockpiles were unchanged for the week, according to the EIA. The S&P Global Platts survey forecast supply increases of 160,000 barrels for gasoline, and 500,000 barrels for distillate stocks.

On Nymex Wednesday, July gasoline RBN8, +2.93% �was up 2.8% at $2.133 a gallon and July heating oil RBN8, +2.93% �traded at $2.180 a gallon, up 2.4%.

July natural gas NGN18, +1.63% �rose 1.8% to $2.992 per million British thermal units, ahead of the contract��s expiration at the end of the trading session.

The oil-price gains came after Brent and WTI closed up Tuesday by more than 2% and nearly 4%, respectively, following threats by the U.S. to sanction countries that don��t cut their imports of Iranian crude to ��zero�� by Nov. 4.

Tuesday��s announcement by the U.S. State Department ��may well have been designed to ramp up the pressure on the Iranian regime, but it is also likely to exert further upward pressure on U.S. prices,�� said Michael Hewson, chief market analyst at CMC Markets UK.

Buyers of Iranian crude had expected the U.S. would allow them a bigger window for winding down their purchases.

President Donald Trump last month pulled the U.S. out of a 2015 international agreement to curb Iran��s nuclear program, setting the stage for the reimposition of economic sanctions on the Islamic Republic that were already expected to hinder its oil exports.

Iran currently exports around 2.4 million barrels a day of crude. Analysts had estimated that anywhere between 400,000 to a 1 million barrels could be at risk once sanctions are fully reinstated in six months.

A ��total stop [of Iranian exports] is unlikely to happen but the more aggressive tone [from the U.S.] suggests there may be a much bigger reduction in Iranian flows than the market has so far priced in,�� analysts at consultancy JBC Energy wrote in a note Wednesday.

The comments out of the U.S. on Tuesday came as Saudi Arabia �� the world��s largest exporter of crude �� said it would raise its own production from 10.8 million barrels a day this month to 11 million barrels a day in July. The move was meant to help ��counter the impact�� of sanctions on Iran, according to Tamas Varga, an analyst at brokerage PVM Oil Associates Ltd.

This past weekend, the Organization of the Petroleum Exporting Countries and Russia agreed to begin ramping up production next month by up to 1 million barrels a day, after more than a year of holding back output. The decision comes amid steadily rising oil prices, geopolitical risks to supply �� including in Iran �� and shrinking global inventories.

OPEC and 10 members outside the oil-cartel, including Russia, implemented a pact to cut crude output by around 1.8 million barrels a day, or roughly 2% of global supply, at the beginning of 2017 as part of an effort to rein in a supply glut.

We Want to Hear from You

Join the conversation

Comment Related Topics Futures Commodities Markets Commodity Futures Trading Commission Oil

Sunday, June 24, 2018

Top 10 Safest Stocks To Buy Right Now

tags:MUR,LYV,CGIX,KEY,CVV,CLLS,TTM,APDN,AROC,SRDX,

Safestyle UK (LON:SFE) had its price target hoisted by Liberum Capital from GBX 50 ($0.67) to GBX 60 ($0.81) in a research report released on Tuesday. Liberum Capital currently has a hold rating on the stock.

SFE stock opened at GBX 60.65 ($0.81) on Tuesday. Safestyle UK has a twelve month low of GBX 91.71 ($1.23) and a twelve month high of GBX 325 ($4.36).

Get Safestyle UK alerts:

The business also recently disclosed a dividend, which will be paid on Monday, July 9th. Shareholders of record on Thursday, June 14th will be issued a dividend of GBX 7.50 ($0.10) per share. The ex-dividend date of this dividend is Thursday, June 14th. This represents a yield of 8.72%. This is a boost from Safestyle UK’s previous dividend of $3.75.

Top 10 Safest Stocks To Buy Right Now: Murphy Oil Corporation(MUR)

Advisors' Opinion:
  • [By Stephan Byrd]

    Murphy Oil Co. (NYSE:MUR) has earned an average rating of “Hold” from the twelve analysts that are presently covering the firm, MarketBeat.com reports. Two research analysts have rated the stock with a sell recommendation, seven have issued a hold recommendation, two have assigned a buy recommendation and one has assigned a strong buy recommendation to the company. The average twelve-month target price among analysts that have updated their coverage on the stock in the last year is $31.56.

Top 10 Safest Stocks To Buy Right Now: Live Nation Entertainment, Inc.(LYV)

Advisors' Opinion:
  • [By Motley Fool Staff]

    Right now, it's time for that yearly review of the ones he picked to honor the month, and also the briefly famous pregnant giraffe: five companies, and the first letters of their tickers spelled out A-P-R-I-L. They were Axon Enterprise�(NASDAQ:AAXN), Grupo Aeroportuario del Pacific�(NYSE:PAC), ResMed�(NYSE:RMD), Intuitive Surgical (NASDAQ:ISRG), and Live Nation�(NYSE:LYV).

  • [By Anders Bylund]

    Shares of Live Nation Entertainment (NYSE:LYV) closed 12.5% higher on Friday, following the release of strong first-quarter results. Earlier in the day, share prices jumped as much as 14.9% higher.

  • [By Motley Fool Staff]

    Stock No. 5: That leads us to our "L" stock, and L is Live Nation (NYSE:LYV). This is the company that was formed by a merger of Live Nation, the concert venue and rock-star-promoting business that it is. So many musicians, today, of course, make most of their money on tours, since the sale of CDs, you might have noticed, has dropped off a cliff in recent years. Live Nation, then, bought a merger with Ticketmaster, so this is the company that sells you the tickets to come into its venues to watch the entertainment that it's promoting. It's a tremendously powerful model.

Top 10 Safest Stocks To Buy Right Now: Cancer Genetics, Inc.(CGIX)

Advisors' Opinion:
  • [By Lisa Levin]

    Cancer Genetics, Inc. (NASDAQ: CGIX) is expected to report quarterly loss at $0.13 per share on revenue of $8.20 million.

    Sypris Solutions, Inc. (NASDAQ: SYPR) is projected to report quarterly loss at $0.07 per share on revenue of $20.35 million.

  • [By Max Byerly]

    OpGen (NASDAQ: OPGN) and Cancer Genetics (NASDAQ:CGIX) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, analyst recommendations, dividends, institutional ownership, valuation, profitability and risk.

  • [By Max Byerly]

    Cancer Genetics Inc (NASDAQ:CGIX) was the recipient of a significant drop in short interest in the month of May. As of May 31st, there was short interest totalling 565,972 shares, a drop of 38.5% from the May 15th total of 919,865 shares. Approximately 2.5% of the shares of the company are short sold. Based on an average trading volume of 207,962 shares, the short-interest ratio is currently 2.7 days.

Top 10 Safest Stocks To Buy Right Now: KeyCorp(KEY)

Advisors' Opinion:
  • [By Stephan Byrd]

    Gifford Fong Associates acquired a new stake in shares of KeyCorp (NYSE:KEY) in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 30,000 shares of the financial services provider’s stock, valued at approximately $587,000.

  • [By Max Byerly]

    Get a free copy of the Zacks research report on KeyCorp (KEY)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By ]

    That said, I never completely abandoned the space. I remain long Citigroup (C) , I am flat KeyCorp (KEY) , having managed to maximize that trade earlier this year. Recently, your pal even reloaded his Goldman Sachs (GS) long after having trimmed that position appropriately. That, friends, is based on my belief that volatility will allow this legendary firm to reclaim its reputation. This one, I'll watch with great anticipation. They report on Tuesday, April 17. My trigger finger itches now.

Top 10 Safest Stocks To Buy Right Now: CVD Equipment Corporation(CVV)

Advisors' Opinion:
  • [By Shane Hupp]

    News coverage about CVD Equipment (NASDAQ:CVV) has been trending somewhat positive this week, according to Accern. The research group ranks the sentiment of media coverage by monitoring more than twenty million news and blog sources in real time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. CVD Equipment earned a news impact score of 0.07 on Accern’s scale. Accern also assigned news headlines about the industrial products company an impact score of 47.2607770405573 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.

Top 10 Safest Stocks To Buy Right Now: Cellectis S.A.(CLLS)

Advisors' Opinion:
  • [By Stephan Byrd]

    Shares of Cellectis SA (NASDAQ:CLLS) have earned an average recommendation of “Hold” from the nine research firms that are presently covering the company, Marketbeat reports. One investment analyst has rated the stock with a sell recommendation, three have assigned a hold recommendation and five have assigned a buy recommendation to the company. The average 1-year price objective among brokerages that have covered the stock in the last year is $42.00.

Top 10 Safest Stocks To Buy Right Now: Tata Motors Ltd(TTM)

Advisors' Opinion:
  • [By Joseph Griffin]

    Tata Motors (NYSE:TTM) shares reached a new 52-week high and low during mid-day trading on Tuesday . The company traded as low as $22.73 and last traded at $22.79, with a volume of 102407 shares trading hands. The stock had previously closed at $22.92.

  • [By John Rosevear]

    First up is the I-Pace, the crossover SUV from Tata Motors' (NYSE:TTM) Jaguar luxury brand. The I-Pace has already begun shipping in Europe, but it won't arrive in the United States until the second half of 2018.

  • [By Paul Ausick]

    Tata Motors Ltd. (NYSE: TTM) fell by about 2% Monday to post a new 52-week low of $23.82 after closing at $24.30 on Friday. The 52-week high is $37.62. Volume of about 3.6 million was more more than double the daily average of about 1.5 million. The company had no specific news.

  • [By Lisa Levin]

    Check out these big penny stock gainers and losers

    Losers Nevro Corp. (NASDAQ: NVRO) fell 11.6 percent to $81.58 in pre-market trading after reporting wider-than-expected Q1 loss. Hertz Global Holdings, Inc. (NYSE: HTZ) shares fell 8.3 percent to $20.33 in pre-market trading after the company reported a wider-than-expected loss for its first quarter. Zillow Group, Inc. (NASDAQ: Z) fell 7.5 percent to $51.74 in pre-market trading. Zillow reported upbeat earnings for its first quarter, but issued weak sales guidance for the second quarter. Sanchez Energy Corporation (NYSE: SN) fell 7.2 percent to $3.11 in pre-market trading after reporting wider-than-expected Q1 loss. Atossa Genetics Inc. (NASDAQ: ATOS) shares fell 5.5 percent to $4.14 in pre-market trading after rising 11.17 percent on Monday. Albemarle Corporation (NYSE: ALB) fell 5.1 percent to $95.00 in pre-market trading. Albemarle declared a quarterly dividend of $0.335 per share. Tata Motors Limited (NYSE: TTM) fell 4.8 percent to $23.80 in pre-market trading. Ormat Technologies, Inc. (NYSE: ORA) fell 4.5 percent to $57.14 in pre-market trading after reporting Q1 results. Kitov Pharma Ltd (NASDAQ: KTOV) shares fell 4.3 percent to $2.25 in pre-market trading after gaining 1.73 percent on Monday. 51job, Inc. (NASDAQ: JOBS) shares fell 4.2 percent to $93 in pre-market trading after rising 3.55 percent on Monday
  • [By Logan Wallace]

    Shares of Tata Motors Limited (NYSE:TTM) have been assigned an average rating of “Hold” from the eight brokerages that are currently covering the firm, MarketBeat.com reports. Three analysts have rated the stock with a sell recommendation, three have assigned a hold recommendation and two have assigned a buy recommendation to the company. The average 12-month price target among brokerages that have issued a report on the stock in the last year is $30.00.

Top 10 Safest Stocks To Buy Right Now: Applied DNA Sciences Inc(APDN)

Advisors' Opinion:
  • [By Logan Wallace]

    NV5 Global (NASDAQ: NVEE) and Applied DNA Sciences (NASDAQ:APDN) are both small-cap business services companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, earnings, analyst recommendations, valuation, institutional ownership, dividends and risk.

  • [By Max Byerly]

    These are some of the media headlines that may have effected Accern Sentiment’s rankings:

    Get Applied DNA Sciences alerts: Applied DNA Sciences’ (APDN) CEO James Hayward on Q2 2018 Results – Earnings Call Transcript (seekingalpha.com) Edited Transcript of APDN earnings conference call or presentation 3-May-18 8:30pm GMT (finance.yahoo.com) Applied DNA Sciences: Fiscal 2Q Earnings Snapshot (finance.yahoo.com) Applied DNA Sciences (APDN) Stock Rating Upgraded by ValuEngine (americanbankingnews.com) Applied DNA Reports Fiscal Second Quarter 2018 Financial Results (finance.yahoo.com)

    A number of research analysts have issued reports on the stock. Maxim Group set a $5.00 price target on shares of Applied DNA Sciences and gave the stock a “buy” rating in a report on Friday, April 6th. ValuEngine raised shares of Applied DNA Sciences from a “strong sell” rating to a “sell” rating in a report on Friday, February 2nd.

  • [By Shane Hupp]

    Ascent Capital Group (NASDAQ: ASCMA) and Applied DNA Sciences (NASDAQ:APDN) are both small-cap industrial products companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, dividends, risk, profitability, earnings and institutional ownership.

Top 10 Safest Stocks To Buy Right Now: Archrock, Inc.(AROC)

Advisors' Opinion:
  • [By Logan Wallace]

    Engineers Gate Manager LP boosted its stake in Archrock Inc (NYSE:AROC) by 241.6% in the 1st quarter, according to its most recent filing with the SEC. The fund owned 95,336 shares of the energy company’s stock after purchasing an additional 67,426 shares during the period. Engineers Gate Manager LP’s holdings in Archrock were worth $834,000 at the end of the most recent quarter.

  • [By Tyler Crowe]

    After years of struggling with the precipitous decline in oil prices and an onerous debt load, management at Archrock (NYSE:AROC) decided to bite the bullet and buy out its subsidiary master limited partnership Archrock Partners. According to management, the deal would free up some cash and lower its cost of capital. The combination of these two things would make it easier to grow the business and take advantage of the monumental growth of natural gas production in the U.S.

Top 10 Safest Stocks To Buy Right Now: SurModics Inc.(SRDX)

Advisors' Opinion:
  • [By Max Byerly]

    Lombard Medical Technologies (OTCMKTS: EVARF) and SurModics (NASDAQ:SRDX) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, analyst recommendations, risk, institutional ownership, dividends, valuation and earnings.

  • [By Ethan Ryder]

    Shares of SurModics, Inc. (NASDAQ:SRDX) hit a new 52-week high and low during trading on Tuesday . The stock traded as low as $47.30 and last traded at $47.20, with a volume of 902 shares. The stock had previously closed at $46.50.

Wednesday, June 20, 2018

Cytokinetics (CYTK) Price Target Cut to $13.00

Cytokinetics (NASDAQ:CYTK) had its price target cut by investment analysts at Piper Jaffray Companies to $13.00 in a note issued to investors on Monday. The firm currently has an “overweight” rating on the biopharmaceutical company’s stock. Piper Jaffray Companies’ price objective would indicate a potential upside of 55.69% from the stock’s previous close.

Several other research analysts have also recently issued reports on CYTK. Cowen reaffirmed a “buy” rating and issued a $11.00 target price on shares of Cytokinetics in a report on Tuesday, February 20th. Morgan Stanley lifted their target price on shares of Cytokinetics from $17.00 to $18.00 and gave the stock an “overweight” rating in a report on Wednesday, February 21st. BidaskClub upgraded shares of Cytokinetics from a “strong sell” rating to a “sell” rating in a research note on Tuesday, March 6th. ValuEngine lowered shares of Cytokinetics from a “sell” rating to a “strong sell” rating in a research note on Thursday, March 29th. Finally, Cantor Fitzgerald set a $10.00 price target on shares of Cytokinetics and gave the stock a “hold” rating in a research note on Tuesday, April 24th. Four research analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. Cytokinetics currently has a consensus rating of “Buy” and a consensus price target of $15.56.

Get Cytokinetics alerts:

Shares of Cytokinetics stock opened at $8.35 on Monday. The company has a debt-to-equity ratio of 0.32, a current ratio of 7.07 and a quick ratio of 7.07. The stock has a market capitalization of $536.56 million, a price-to-earnings ratio of -3.22 and a beta of 1.17. Cytokinetics has a 52-week low of $6.75 and a 52-week high of $15.95.

Cytokinetics (NASDAQ:CYTK) last issued its earnings results on Thursday, April 26th. The biopharmaceutical company reported ($0.56) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.50) by ($0.06). The firm had revenue of $5.27 million during the quarter, compared to analysts’ expectations of $5.50 million. Cytokinetics had a negative return on equity of 99.50% and a negative net margin of 172.27%. research analysts predict that Cytokinetics will post -1.99 EPS for the current year.

In related news, EVP Fady Ibraham Malik sold 3,000 shares of the business’s stock in a transaction that occurred on Thursday, June 7th. The shares were sold at an average price of $8.95, for a total transaction of $26,850.00. Following the completion of the sale, the executive vice president now directly owns 96,067 shares in the company, valued at $859,799.65. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Robert I. Blum sold 4,000 shares of the business’s stock in a transaction that occurred on Tuesday, June 5th. The shares were sold at an average price of $8.28, for a total transaction of $33,120.00. Following the sale, the chief executive officer now owns 176,022 shares of the company’s stock, valued at $1,457,462.16. The disclosure for this sale can be found here. Insiders sold 15,000 shares of company stock valued at $123,570 over the last quarter. Company insiders own 5.10% of the company’s stock.

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Virtu Financial LLC bought a new stake in Cytokinetics during the fourth quarter valued at approximately $112,000. Teacher Retirement System of Texas bought a new stake in Cytokinetics during the fourth quarter valued at approximately $113,000. DRW Securities LLC bought a new stake in Cytokinetics during the first quarter valued at approximately $101,000. Ellington Management Group LLC bought a new stake in Cytokinetics during the fourth quarter valued at approximately $128,000. Finally, Granite Investment Advisors LLC bought a new stake in Cytokinetics during the fourth quarter valued at approximately $151,000. Institutional investors own 68.01% of the company’s stock.

About Cytokinetics

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. It is developing small molecule drug candidates primarily engineered to increase muscle function and contractility.

Analyst Recommendations for Cytokinetics (NASDAQ:CYTK)

Tuesday, June 19, 2018

Kingfisher Capital LLC Has $618,000 Stake in Alibaba Group Holding Ltd (BABA)

Kingfisher Capital LLC increased its holdings in shares of Alibaba Group Holding Ltd (NYSE:BABA) by 25.7% during the first quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 3,369 shares of the specialty retailer’s stock after acquiring an additional 688 shares during the period. Kingfisher Capital LLC’s holdings in Alibaba Group were worth $618,000 as of its most recent SEC filing.

A number of other institutional investors also recently modified their holdings of BABA. Keybank National Association OH lifted its stake in Alibaba Group by 43.7% in the 4th quarter. Keybank National Association OH now owns 16,801 shares of the specialty retailer’s stock valued at $2,897,000 after buying an additional 5,109 shares in the last quarter. Global Financial Private Capital LLC lifted its stake in Alibaba Group by 46.7% in the 4th quarter. Global Financial Private Capital LLC now owns 3,284 shares of the specialty retailer’s stock valued at $566,000 after buying an additional 1,046 shares in the last quarter. MUFG Americas Holdings Corp purchased a new position in Alibaba Group in the 4th quarter valued at about $101,000. Ahrens Investment Partners LLC lifted its stake in Alibaba Group by 64.3% in the 4th quarter. Ahrens Investment Partners LLC now owns 4,517 shares of the specialty retailer’s stock valued at $779,000 after buying an additional 1,767 shares in the last quarter. Finally, GWM Advisors LLC lifted its stake in Alibaba Group by 22.8% in the 4th quarter. GWM Advisors LLC now owns 2,991 shares of the specialty retailer’s stock valued at $569,000 after buying an additional 555 shares in the last quarter. 37.91% of the stock is currently owned by hedge funds and other institutional investors.

Get Alibaba Group alerts:

Shares of BABA stock traded down $1.33 during trading on Monday, hitting $206.67. 312,993 shares of the stock traded hands, compared to its average volume of 16,003,160. The firm has a market cap of $532.72 billion, a PE ratio of 51.27, a PEG ratio of 1.29 and a beta of 2.54. The company has a debt-to-equity ratio of 0.27, a quick ratio of 1.97 and a current ratio of 1.89. Alibaba Group Holding Ltd has a 52-week low of $133.55 and a 52-week high of $211.70.

Alibaba Group (NYSE:BABA) last released its quarterly earnings results on Friday, May 4th. The specialty retailer reported $0.54 EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $0.65 by ($0.11). The firm had revenue of $9.87 billion for the quarter, compared to analysts’ expectations of $9.36 billion. Alibaba Group had a net margin of 25.39% and a return on equity of 16.61%. During the same period in the previous year, the firm posted $0.63 EPS. equities research analysts predict that Alibaba Group Holding Ltd will post 5.36 EPS for the current fiscal year.

A number of brokerages recently weighed in on BABA. Wells Fargo & Co raised their price target on shares of Alibaba Group from $230.00 to $250.00 and gave the company an “outperform” rating in a research note on Thursday. Susquehanna Bancshares raised their price target on shares of Alibaba Group from $220.00 to $305.00 and gave the company a “positive” rating in a research note on Thursday, June 7th. BNP Paribas began coverage on shares of Alibaba Group in a research note on Thursday. They issued a “buy” rating on the stock. Raymond James reaffirmed a “strong-buy” rating and issued a $300.00 price target (up from $250.00) on shares of Alibaba Group in a research note on Thursday, May 24th. Finally, MKM Partners raised their price target on shares of Alibaba Group from $260.00 to $280.00 and gave the company a “buy” rating in a research note on Friday, May 18th. One analyst has rated the stock with a hold rating, thirty-one have issued a buy rating and two have given a strong buy rating to the company’s stock. The stock has a consensus rating of “Buy” and a consensus price target of $224.75.

Alibaba Group Company Profile

Alibaba Group Holding Limited, through its subsidiaries, operates as an online and mobile commerce company in the People's Republic of China and internationally. The company operates in four segments: Core Commerce, Cloud Computing, Digital Media and Entertainment, and Innovation Initiatives and Others.

Institutional Ownership by Quarter for Alibaba Group (NYSE:BABA)